All In Biotech

Free tool

FAERS Monitor: Vraylar

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 204370 or its brand name (Vraylar, Cariprazine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

9,636

Serious

3,459

36% of reports

Hospitalization

1,349

Death reported

258

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use1,083
  • drug ineffective566
  • weight increased501
  • akathisia434
  • anxiety392
  • tardive dyskinesia392
  • tremor378
  • nausea373
  • fatigue368
  • insomnia354
  • suicidal ideation337
  • depression296
  • dizziness290
  • somnolence253
  • feeling abnormal231

Reports by year received

View as table
YearReports
20112
20151
2016156
2017337
2018415
2019890
20201,030
2021853
2022850
20231,259
20241,294
20251,516
20261,033

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,523 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
akathisiaSignal43471.765.329,232
tardive dyskinesiaSignal39230.727.911,109
suicidal ideationSignal3378.17.32,079
tremorSignal3785.04.51,205
weight increasedSignal5014.94.51,561
anxietySignal3923.02.7530
insomniaSignal3542.92.6445
depressionSignal2962.82.5355
somnolenceSignal2532.72.4281
off label useSignal1,0832.72.61,208
feeling abnormalSignal2312.11.9134
dizziness2901.31.117
fatigue3681.00.90
nausea3731.00.90
drug ineffective5660.90.92

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.